| 13.53 -0.01 (-0.07%) | 10-17 15:51 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 15.02 | 1-year : | 17.25 |
| Resists | First : | 12.85 | Second : | 14.77 |
| Pivot price | 12.66  |
|||
| Supports | First : | 9.76 | Second : | 8.12 |
| MAs | MA(5) : | 9.76 |
MA(20) : | 12.97 |
| MA(100) : | 14.99 |
MA(250) : | 17.22 |
|
| MACD | MACD : | -1.2 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 19.1 | |||
| 52-week | High : | 22.88 | Low : | 9.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CHNA ] has closed above bottom band by 15.2%. Bollinger Bands are 414.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.78 - 9.85 | 9.85 - 9.9 |
| Low: | 9.64 - 9.71 | 9.71 - 9.77 |
| Close: | 9.67 - 9.79 | 9.79 - 9.88 |
The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.
Fri, 27 Oct 2023
This Week in ETFs: 4 New Single-Stock Funds Debut - ETF Trends
Sun, 12 Mar 2023
Chinese biotech and pharmaceuticals ETF - ETF Stream
Fri, 01 Jul 2022
Best Performing ETFs For June 2022 - ETF Focus on TheStreet: ETF research and Trade Ideas - TheStreet
Wed, 27 Apr 2022
ETFs With The Highest & Lowest Trading Spreads - Yahoo Finance
Thu, 17 Mar 2022
What Happens to Your ETFs if Chinese ADRs Delist? - hk.morningstar.com
Thu, 10 Mar 2022
Biotech Stocks: Why China-Based Plays, Like BeiGene, Are In Trouble - Investor's Business Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|